KR20220095074A - Black ginseng extract for preventing or improving inflammatory bowl disease and manufacturing method thereof - Google Patents

Abstract

The present invention relates to a black ginseng extract, and more specifically, to a black ginseng extract for alleviating inflammatory bowel disease, and a method for manufacturing the same. The method for manufacturing the black ginseng extract for alleviating inflammatory bowel disease according to the present invention enables high yields of various types of ginsenosides with a short manufacturing time.

Description

Black ginseng extract for preventing or improving inflammatory bowl disease and manufacturing method thereof

The present invention relates to a black ginseng extract, and more particularly, to a black ginseng extract for preventing or improving inflammatory bowel disease and a method for preparing the same.

Inflammatory diseases are one of the most important health problems worldwide. Inflammation is usually a protective response of body tissues to foreign substances or harmful stimuli. Inflammation can be caused by infectious causes such as bacteria, viruses, and parasites; physical causes such as burns or radiation; chemicals such as toxins, drugs or industrial agents; It is associated with immune responses, such as allergies and autoimmune responses, or oxidative stress.

Inflammation is characterized by pain, redness, swelling, fever, and loss of function in the affected area. These symptoms are the result of complex interactions between cells of the immune system. The cellular response results in an interactive network of multiple inflammatory mediators.

Meanwhile, inflammatory bowel disease (IBD) is a representative disease among inflammatory diseases. Inflammatory bowel disease refers to a chronic inflammatory disease in which inflammation or ulceration occurs in the intestine due to unknown causes, such as ulcerative colitis (UC), Crohn's disease (CD), and Behçet's disease.

It is known that inflammatory bowel disease presents with intestinal pathological signs such as weight loss, diarrhea accompanied by mucus or blood, fever, intestinal motility disorder, and shortness of the colon. In almost all patients with ulcerative colitis, inflammation is found in the rectum, and the extent of inflammation is throughout the large intestine. Therefore, it is known that in the presence of inflammatory bowel disease, various inflammatory cytokines are secreted from the intestinal mucosa and inflammatory signal transduction is activated.

Ulcerative colitis is a recurrent and intractable intestinal disease of the digestive system. In clinical practice, abdominal pain, diarrhea, and bloody mucus are the main symptoms. Normal colon tissue is divided into 4 layers: mucous membrane, submucosa, muscle layer, and serous membrane. With the development of ulcerative colitis, pathological changes appear in the mucosa and submucosal tissues. As the ulcer is formed, infiltration of inflamed cells occurs in adjacent layers, and non-specific changes are observed in which inflammation occurs in crypt abscess and surrounding blood vessels, and various inflammatory cells such as neutrophils and eosinophils appear. This disease is common in countries that mainly eat meat, such as Europe and the United States, and has recently been significantly increasing in Korea. However, the cause and pathogenesis of this disease are relatively complex, and thus the exact cause is still unknown.

Currently, as a treatment for inflammatory bowel disease, 5-aminosalicylic acid (5-ASA) series drugs that block the production of prostaglandins, for example, sulfasalazine, etc. are used, or steroids are used. I am using immunosuppressants. However, when these drugs are taken for a long time, there are problems in that side effects, toxicity, and tolerance occur in relation to the dosage of the drug.

Accordingly, in recent years, extracts of natural products or processed natural products that can reduce the side effects of chemical drugs are used for alleviation or treatment of various inflammatory diseases. However, extracts of known natural products or processed natural products are not effective enough in alleviating, treating and preventing inflammatory bowel disease.

Korean Patent Publication No. 2020-0027624 A1 (published on March 31, 2020)

The present invention has been devised to solve the above problems, and it is possible to obtain a high yield of various types of ginsenosides with a short manufacturing time, and to prevent inflammatory bowel disease, which has low cytotoxicity and an excellent effect on inflammatory bowel disease, An object of the present invention is to provide a black ginseng extract for improvement and treatment, a method for preparing the same, and a health functional food and pharmaceutical composition using the same.

In order to solve the above problems, the present invention includes (1) steaming fresh ginseng at 85 to 105° C. for 3 to 7 hours and drying the steamed fresh ginseng at 50 to 70° C. for 6 to 10 hours in one set. To provide a method for producing black ginseng extract for preventing or improving inflammatory bowel disease, comprising the steps of manufacturing black ginseng by repeatedly performing 3 to 7 sets and (2) extracting and concentrating the black ginseng to prepare a black ginseng extract.

According to an embodiment of the present invention, the step (2) comprises the steps of (2)-1 extracting the mixed solution containing black ginseng and an organic solvent at 60 to 80° C. for 20 to 28 hours repeatedly 2 to 4 times and ( 2)-2 may include the step of concentrating the extracted black ginseng under reduced pressure to prepare a black ginseng extract.

In addition, the organic solvent is ethanol having a concentration of 60% to 80%, and the mixed solution of step (2)-1 may contain black ginseng and an organic solvent in a weight ratio of 1:7 to 13 by weight.

In addition, before step (1), drying at a temperature of 60° C. or higher for 2 hours or more may not be included.

In addition, the present invention provides a black ginseng extract for preventing or improving inflammatory bowel disease extracted by the manufacturing method according to the present invention.

In addition, the black ginseng extract of the present invention contains ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rh4, ginsenoside Rg3(S), ginsenoside Rk1 and ginsenoside Rg5 in a total amount of 19.0 mg/g or more. may include

In addition, the black ginseng extract of the present invention may have an inhibition rate of intestinal inflammation measured based on Equation 1 below 35.0% or more.

[Equation 1]

Inhibition rate of intestinal inflammation (%) = (expression of inflammation in the colon in the inflammation-induced test group - the amount of inflammation in the colon in the administration of black ginseng extract and the inflammation-induced test group)/(expression of inflammation in the colon in the inflammation-induced test group)×100 %

In Equation 1, the inflammation-inducing experimental group was the oral administration of DSS (dextaran sulfate sodium) at a concentration of 4% by volume, and then, 12 or 13 days later, the amount of inflammation in the colon was measured, and the Black ginseng extract administration and inflammation-induced experimental group was to measure the amount of inflammation in the colon after the oral administration of 2.5 mg/kg of black ginseng extract and DSS at a concentration of 4% by volume, and the same time as that of the inflammation-induced experimental group.

In addition, the present invention is the black ginseng extract; And/or a black ginseng extract fraction obtained from the black ginseng extract; provides a health functional food for preventing or improving inflammatory bowel disease, including as an active ingredient.

In addition, the present invention is the black ginseng extract; And/or a black ginseng extract fraction obtained from the black ginseng extract; provides a pharmaceutical composition for preventing or improving inflammatory bowel disease, comprising as an active ingredient.

In addition, the present invention can prevent or improve inflammatory bowel disease by inhibiting the activity of macrophage cells in the colon.

The method for producing black ginseng extract for improving inflammatory bowel disease according to the present invention enables high yield of various types of ginsenosides while the production time is short. In addition, the black ginseng extract obtained thereby has low cytotoxicity and at the same time exhibits excellent effects in alleviating, improving, treating and preventing inflammatory bowel disease, so it can be applied to various health foods and pharmaceutical compositions.

1 is a photograph of observing the amount of changes in the anus and feces of the black ginseng extract according to an embodiment of the present invention on the enteritis-induced animal group through DSS (dextaran sulfate sodium).
Figure 2 is a graph of the colitis scoring results evaluated through the amount of change in the anus and feces on the animal group induced with enteritis through DSS of the black ginseng extract according to an embodiment of the present invention.
3 is a bioimage (PET) image related to the activity level of macrophage cells that the black ginseng extract according to an embodiment of the present invention exerts on enteritis-induced animal groups through DSS.
4 and 5 are graphs of the observation of the change in the length of the colon and the result of measuring the length of the large intestine that the black ginseng extract according to an embodiment of the present invention exerts on the group of animals induced by DSS through DSS.

Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily implement them. The present invention may be embodied in many different forms and is not limited to the embodiments described herein.

The black ginseng extract for preventing or improving inflammatory bowel disease according to an embodiment of the present invention includes (1) steaming fresh ginseng at 85 to 105° C. for 3 to 7 hours and steaming fresh ginseng at 50 to 70° C. for 6 to 10 hours. It may be prepared including the steps of manufacturing black ginseng by repeating 3 to 7 sets of drying as one set, and (2) extracting and concentrating the black ginseng to prepare a black ginseng extract.

First, the (1) step of producing the black ginseng; will be described.

In step 1, the steaming may be performed by steaming fresh ginseng at 85 to 105° C. for 3 to 7 hours, preferably at 90 to 100° C. for 4 to 6 hours. If the temperature and time conditions of the steaming are not satisfied, ginsenosides Rg1, Rb1, Rh4, Rk1, Rg3(S) and/or Rg5, preferably Rb1, Rk1, Rg3(S) and/or Rg5 It may be difficult to obtain a black ginseng extract containing a high content of

In addition, in step (1), the drying may include drying steamed fresh ginseng at 50 to 70° C. for 6 to 10 hours, preferably, steamed fresh ginseng at 55 to 65° C. for 7 to 9 hours. If the drying temperature and time conditions are not satisfied, ginsenoside may not be included in a high content.

And, the step (1) may be repeated in 3 to 7 sets, preferably in a total of 4 to 6 sets, with the steaming and drying process as one set. If the number of repetitions of the steaming and drying process is small, the ginsenoside content in the black ginseng extract may be small, and even if the number of repetitions exceeds 7 sets, there may be no further increase in the ginsenoside content, so repeat the steaming and drying within the above range It is good to do

On the other hand, according to an embodiment of the present invention, the step of washing and drying fresh ginseng before step (1) may be further included. The washing and drying step is not particularly limited in the present invention, as washing and drying may be performed by a method that can be commonly used in the art.

On the other hand, the black ginseng extract manufacturing method according to the present invention may not include the step of drying at a temperature of 60° C. or higher for 2 hours or more before step (1), preferably, before step (1), 70 It may not include the step of drying at a temperature of ℃ or higher for 2.5 hours or more, and more preferably, before step (1), the step of drying at a temperature of 80℃ or higher for 3 hours or more may not be included. Before the step (1), it is possible to obtain a black ginseng extract containing a high content of ginsenosides with a short manufacturing time as it does not include the step of drying at a temperature of 60° C. or higher for 2 hours or more, and has no cytotoxicity. The efficacy of preventing or improving inflammatory bowel disease can express an exceptionally excellent effect.

Next, the step (2) is, step (2)-1 to obtain an extract by repeating the extraction process of a mixture containing black ginseng and an organic solvent; and (2)-2 step of preparing a black ginseng extract by concentrating the extract under reduced pressure.

In step (2)-1, the extraction process may be performed by repeating the mixed solution containing black ginseng and an organic solvent 2 to 4 times at 60 to 80° C. for 20 to 28 hours, preferably at 65 to 75° C. The extraction process can be performed by repeating 3 to 4 times for 22 to 26 hours. If the extraction temperature, time and/or the number of repetitions are not satisfied, the specific ginsenoside content in the black ginseng extract may be small, so it is better to repeat the extraction process within the above range.

On the other hand, the organic solvent can be used without limitation as long as it is a material that can be used as an extraction solvent in general, and preferably at least one organic solvent selected from the group consisting of methanol, ethanol, fermented ethanol and ethyl acetate can be used. , More preferably, ethanol may be used. When ethanol is used as the organic solvent, an aqueous ethanol solution having a concentration of 60 to 80% by volume can be used, preferably an aqueous ethanol solution having a concentration of 65 to 75% by volume, more preferably 67 to 73% by volume. An aqueous ethanol solution may be used. If the concentration of the aqueous ethanol solution is out of the above range, the ginsenoside content in the extracted extract may be small.

In addition, the mixed solution may include the black ginseng and the organic solvent in a weight ratio of 1: 7 to 13, preferably 1: 8 to 12 by weight. If the weight ratio of the black ginseng and the organic solvent is out of the above range, it is impossible to obtain an extract containing a high content of the extracted ginsenosides Rb1, Rh4, Rk1 and/or Rg5, and the anti-inflammatory effect may be reduced.

And, the step (2)-2 is a step of preparing a black ginseng extract by concentrating the extract under reduced pressure. As the conditions for the concentration under reduced pressure can be used without limitation as long as the conditions of concentration under reduced pressure that can be commonly used are, in the present invention, This is not particularly limited.

In addition, the step of filtering the extract between the steps (2)-1 and (2)-2 may be further included, but is not limited thereto. In addition, freeze-drying and/or vacuum-drying may be optionally further performed after the concentration under reduced pressure, but the present invention is not limited thereto.

In the present invention, the black ginseng extract prepared by the above-described manufacturing method may contain a specific ginsenoid in a high content.

The black ginseng extract contains ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rh4, ginsenoside Rg3(S), ginsenoside Rk1 and ginsenoside Rg5, preferably ginsenoside Rg1 0.10 ~ 0.30 mg/g, ginsenoside Rb1 2.00 ~ 3.20 mg/g , ginsenoside Rh4 4.00 ~ 6.00 mg/g, ginsenoside Rg3(S) 3.00 ~ 5.50 mg/g, ginsenoside Rk1 2.80 ~ 4.50 mg/g and ginsenoside Rg5 may be included in an amount of 4.50 to 6.50 mg/g, more preferably ginsenoside Rg1 0.15 to 0.30 mg/g, ginsenoside Rb1 2.20 to 3.00 mg/g, ginsenoside Side Rh4 4.10 ~ 5.50 mg/g, ginsenoside Rg3(S) 3.40 ~ 5.20 mg/g, ginsenoside Rk1 3.00 ~ 4.40 mg/g and ginsenoside Rg5 4.80 ~ 6.30 mg/g have.

In addition, the black ginseng extract may contain a total amount of ginsenosides (Rg1, Rb1, Rh4, Rg3(S), Rk1, Rg5) of 15.5 mg/g or more, preferably 17.5-23.5 mg/g, , The total amount of these ginsenoids is improved by about 200 times or more compared to the total amount of ginsenosides extracted from conventional black ginseng, and may contain active ingredients capable of preventing, improving or treating inflammatory bowel disease at high concentrations.

In addition, since the black ginseng extract contains less than 0.08 μg/kg of harmful components such as benzopyrene, various side effects due to harmful components such as benzopyrene can be minimized.

In addition, the black ginseng extract may include a total phenol content of 650 mg/100g or more, preferably 670 mg/100g or more, and more preferably 680 mg/100g or more.

The anti-inflammatory composition of the present invention may include a fraction (a black ginseng extract fraction) of the black ginseng extract prepared by the above-described manufacturing method as an active ingredient.

The black ginseng extract fraction may be obtained by using a known fractionation method of the black ginseng extract prepared by the above-described method to obtain a black ginseng extract fraction containing a large amount of ginsenoside components. In addition, specific ginsenoside components such as Rg1, Rb1, Rh4, Rg3(S), Rk1, Rg5 are obtained by performing a separation process of specific ginsenoside components from the black ginseng extract fraction, preferably Rb1, Rh4, Rg3 (S), Rk1 and/or Rg5 can also be obtained at high concentrations.

The separation may be used without limitation as long as it is a conventional separation method, and preferably may be performed by any one or more methods selected from silica gel column chromatography and reverse phase silica gel column chromatography, but is not limited thereto. In addition, a process of purifying the black ginseng extract fraction or a specific ginsenoside component obtained by separation therefrom may be performed.

For a preferred example, the anti-inflammatory composition of the present invention includes the black ginseng extract fraction obtained by fractionation from the black ginseng extract by the above method, and the black ginseng extract fraction is selected from among the ginsenosides Rb1, Rh4, Rg3(S), Rk1 and Rg5. It may contain two or more selected may include

In addition, the black ginseng extract fraction contains Rh4, Rg3(S) and Rg5 in a total amount of 12.50 mg/g or more, more preferably ginsenosides Rh4, Rg3(S) and Rg5 in a total amount of 13.0 to 15.50 mg/g can be included as

The black ginseng extract (and/or black ginseng extract fraction) of the present invention described above can suppress the expression of intestinal inflammation by inhibiting the activity of intestinal macrophage cells.

In addition, the present invention is the black ginseng extract described above; and a black ginseng extract fraction fractionated from the black ginseng extract; It is also possible to provide a health functional food for preventing or improving inflammatory bowel disease comprising at least one selected from among as an active ingredient.

That is, the black ginseng extract and / or black ginseng extract fraction described above for the purpose of preventing and improving inflammatory bowel disease may be added to the food composition.

In this case, the extract (and/or black ginseng extract fraction) may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prophylactic, health or therapeutic treatment).

There is no particular limitation on the type of the food. Examples of food include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes. and includes all health foods in the ordinary sense.

In addition, in the case of a health beverage composition, it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in a conventional beverage. The above-mentioned natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumartin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention, but is not limited thereto, and may be appropriately changed according to preference.

In addition, various other nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonated beverages It may contain a carbonation agent, etc. The proportion of these additives is not very important, but is generally selected in the range of 0.01 to 0.1% by weight based on the total weight of the composition. In addition, it may contain the pulp for the production of natural fruit juice, fruit juice beverage and vegetable beverage. The ratio of the pulp is not very important, but is generally selected in the range of 0.01 to 10% by weight based on the total weight of the composition. These components may be used independently or in combination.

In addition, the present invention is the black ginseng extract described above; and a black ginseng extract fraction fractionated from the black ginseng extract; It may be provided as a pharmaceutical composition comprising one or more selected from among as an active ingredient.

The present invention will be described in more detail through the following examples, but the following examples are not intended to limit the scope of the present invention, which should be construed to aid understanding of the present invention.

[Example]

Example 1: Preparation of black ginseng extract

(1) Production of black ginseng

After steaming 873 kg of 5-year-old fresh ginseng (produced in March, 2020) at 95° C. for 5 hours under no pressure conditions, and drying it with hot air at 60° C. for 8 hours, the steaming and hot air drying were repeated 5 sets. to prepare 203 kg of black ginseng (yield 23.3%).

(2) Preparation of black ginseng extract

The mixture obtained by mixing 90 kg of black ginseng with 70% by volume of ethanol and 1:10 by weight was extracted three times at 70° C. for 24 hours, filtered, and then concentrated under reduced pressure to obtain 36.92 kg of black ginseng concentrate powder (yield 41.02). %) and then freeze-drying to prepare a black ginseng extract.

Comparative Example 1

Black ginseng extract was prepared in the same manner as in Example 1, but using black ginseng sold by Kyungbang Shinyak Co., Ltd. instead of black ginseng prepared in (1) of Example 1, the same extraction process as in Example 1, concentration under reduced pressure, and freeze-drying to prepare a black ginseng extract.

Experimental Example 1

The black ginseng extract prepared in Example 1 and Comparative Example 1 was subjected to HPLC chromatogram to analyze the ginsenoside (Rg1, Rb1, Rh4, Rg3(S), Rk1 and Rg5) content, and the results are shown below. Table 1 shows.

Ginsenoids (mg/g) Total (mg/g) Benzopyrene (μg/kg) Rg1 Rb1 Rh4 Rg3(S) Rk1 Rg5 Example 1 1 time 0.17 2.35 4.45 3.77 3.19 5.4 19.33 0.07 Episode 2 0.15 2.12 4.49 3.88 3.29 5.57 19.5 0.08 3rd time 0.21 3.01 4.08 3.87 3.08 5.23 19.48 0.06 Average 0.18 2.49 4.34 3.84 3.19 5.4 19.44 0.07 Comparative Example 1 0.03 0.46 0.23 0.06 0.11 0.17 0.09 0.01

As can be seen in Table 1, the ginsenoside Rg1, Rb1, Rh4, Rg3(S), Rk1 and Rg5 contents in the black ginseng extract prepared in Example 1 were very high, and the benzopyrene content was also very low, 0.07 ug/kg or less. could check

In contrast, in Comparative Example 1, it was confirmed that the total total ginsenoside was less than 0.1 mg/g, which was very low compared to Example 1.

Experimental Example 2: Inflammatory bowel disease improvement efficacy test

For an animal model in which enteritis was induced by DSS (dextaran sulfate sodium), the inflammatory bowel disease improvement efficacy of the black ginseng extract according to Example 1 was evaluated.

(1) Experimental animals

The experiment was performed using a C57BL/6 mouse (mouse, male, 6 weeks old) as an animal model.

(2) evaluation of inflammation induction and colitis scoring

The first animal group in which 4% by volume DSS was orally administered with 2.5 mg/kg of black ginseng extract (BG), the second animal group in which 4% by volume DSS was orally administered with a vehicle, no treatment Changes in anal changes and feces for the third animal group (control, control group) were observed, and after oral administration, pictures of changes in anal changes and feces after 8 to 13 days have elapsed are shown in FIG. 1 .

As can be seen from FIG. 1 , it was confirmed that the amount of anal change and fecal change occurring in the animal group administered with DSS was significantly improved in the group administered with black osmosis.

In addition, the colitis scoring criteria according to Table 2 (nature protocols, vol.2, NO.3 2007) and measurement results were analyzed, and the results are shown in Table 3 and FIG. 2 below. The inhibition rate (%) of intestinal inflammation in Table 3 below was measured based on Equation 1 below.

[Equation 1]

Inhibition rate (%) of intestinal inflammation = (expression of inflammation in the colon of the inflammation-induced test group - the amount of expression of inflammation in the colon in the test group administered with black ginseng extract and inflammation-induced)/(expression of inflammation in the colon in the inflammation-induced test group)×100 %

In Equation 1, the inflammation-induced experimental group was administered by oral administration of 4% by volume of DSS (dextaran sulfate sodium) to the test subject, and then the amount of inflammation in the colon was measured after a certain period of time elapsed, and the black ginseng extract was administered And the inflammation-inducing experimental group was to measure the amount of inflammation in the colon after the oral injection of 2.5 mg/kg of black ginseng extract and DSS at a concentration of 4% by volume, and the same time as the inflammation-inducing experimental group.

Scoring system for the comparative analysis of intestinal bleeding score
(score) stool consistency
(stool consistency) blood in the stool 0 Normal Negative hemoccult One Soft but still formed Positive hemoccult 2 very soft Visual presence of blood in the stool
(Blood traces in stool visible) 3 diarrhea rectal bleeding

division
(Score) 8 days passed 9 days passed 10 days passed number of measurements 3rd fauna 2nd fauna 1st fauna 3rd fauna 2nd fauna 1st fauna 3rd fauna 2nd fauna 1st fauna One 0 0 One 0 0 One 0 0 One 2 0 One One 0 One One 0 One One 3 0 One One 0 One One 0 One One 4 0 One One 0 One One 0 One One 5 0 2 One 0 One One 0 One One Average 0 One One 0 0.8 One 0 0.8 One intestinal inflammation
incidence inhibition rate - - 0 - - -20% - - -20% division
(Score) 11 days passed 12 days passed 13 days elapsed number of measurements 3rd fauna 2nd fauna 1st fauna 3rd fauna 2nd fauna 1st fauna 3rd fauna 2nd fauna 1st fauna One 0 0 2 0 0 3 0 0 One 2 0 2 2 0 4 2 0 5 One 3 0 5 2 0 6 2 0 5 One 4 0 4 2 0 6 3 0 5 2 5 0 3 2 0 5 3 0 4 2 Average 0 2.8 2 0 4.2 2.6 0 3.8 1.4 intestinal inflammation
incidence inhibition rate - - 28.57% 0 - 38.10% - - 63.16%

It can be seen from Table 3 and FIG. 2 that the black ginseng extract (BG) and DSS of Example 1 were administered together when compared to the second animal group after 12 days had elapsed after the black ginseng administration. In the case of the third animal group, the inhibition rate of intestinal inflammation was over 35%, and it was confirmed that the intestinal inflammation was reduced to a normal level when 13 days had elapsed.

Experimental Example 3: Measurement of the activity of macrophage cells in the colon

Bioimaging (National Institutes of Health, USA) using optical imaging equipment (AMI HTX (Spectral instruments imaging, USA)) and analysis program (ImageJ (National Institutes of Health, USA)) for the first to third animal groups of Experimental Example 2 Through PET) image analysis, the activity of macrophage cells activated according to the inflammatory response was measured, and the results are shown in FIG. 3 .

As can be seen from FIG. 3 , it was confirmed that the expression level of inflammation was significantly reduced in the black ginseng extract administration group compared to the colon inflammation induced by DSS treatment.

In addition, the colon length was measured to measure the correlation with the inflammatory change, and the results are shown in FIGS. 4 and 5 .

4 and 5, compared with the second animal group, it can be seen that the first animal group treated with the black ginseng extract (BG) according to Example 1 suppressed and improved colon damage due to inflammation inhibition and improvement. .

Through the above Examples and Experimental Examples, it was confirmed that the black ginseng extract (and/or the black ginseng extract fraction) had an excellent inflammatory bowel disease prevention or improvement effect. The black ginseng extract (and/or black ginseng extract fraction) of the present invention can be applied to various functional products such as health functional foods, cosmetics, and pharmaceutical compositions that can prevent and improve inflammatory bowel disease.

Although one embodiment of the present invention has been described above, the spirit of the present invention is not limited to the embodiments presented herein, and those skilled in the art who understand the spirit of the present invention can add components within the scope of the same spirit. , changes, deletions, additions, etc. may easily suggest other embodiments, but this will also fall within the scope of the present invention.

Claims (7)

(1) Repeating 3 to 7 sets of steaming fresh ginseng at 85 ~ 105℃ for 3 ~ 7 hours and drying steamed fresh ginseng at 50 ~ 70℃ for 6 ~ 10 hours for 6 ~ 10 hours is repeated to produce black ginseng. manufacturing; and
(2) preparing a black ginseng extract by extracting and concentrating the black ginseng;
According to claim 1, wherein the step (2),
(2)-1 repeating extraction of a mixture containing black ginseng and an organic solvent 2 to 4 times at 60 to 80° C. for 20 to 28 hours; and
(2)-2 The organic solvent is ethanol having a concentration of 60% to 80%,
The mixed solution of step (2)-1 contains black ginseng and an organic solvent in a weight ratio of 1: 7 to 13; and
(2)-3 Concentrating the extracted black ginseng under reduced pressure to prepare a black ginseng extract; inflammatory bowel disease prevention or improvement method for black ginseng extract comprising a.
A black ginseng extract for preventing or improving inflammatory bowel disease extracted by the manufacturing method according to claim 1.
According to claim 3, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rh4, ginsenoside Rg3(S), ginsenoside Rk1 and ginsenoside Rg5 black ginseng comprising a total amount of 19.0 mg/g or more Black ginseng extract for preventing or improving inflammatory bowel disease, comprising the extract as an active ingredient.
[Claim 4] The black ginseng extract for preventing or improving inflammatory bowel disease according to claim 3, wherein the inhibition rate of intestinal inflammation measured based on the following Equation 1 is 35.0% or more;
[Equation 1]
Inhibition rate (%) of intestinal inflammation = (expression of inflammation in the colon of the inflammation-induced test group - the amount of expression of inflammation in the colon in the test group administered with black ginseng extract and inflammation-induced)/(expression of inflammation in the colon in the inflammation-induced test group)×100 %
In Equation 1, the inflammation-inducing experimental group was administered by oral injection of dextaran sulfate sodium (DSS) at a concentration of 4% by volume, and then the amount of inflammation in the colon was measured after 12 or 13 days have elapsed, and the The black ginseng extract administration and inflammation-inducing experimental group were oral administration of black ginseng extract 2.5 mg/kg and 4% by volume DSS concentration, and then, the amount of inflammation in the colon was measured after the same time elapsed as the inflammation-inducing experimental group.
The black ginseng extract of claim 4 or 5; and a black ginseng extract fraction obtained from the black ginseng extract; A health functional food for preventing or improving inflammatory bowel disease, comprising at least one selected from among as an active ingredient.
The black ginseng extract of claim 4 or 5; and a black ginseng extract fraction obtained from the black ginseng extract; Contains one or more selected from among as an active ingredient,
A pharmaceutical composition for preventing or improving inflammatory bowel disease, characterized in that it inhibits the activity of macrophage cells in the colon.

Images